BBS-Bioactive Bone Substitutes Plc 221 0 Kommentare BBS arranges a rights offering of approximately maximum EUR 2.9 million

BBS-Bioactive Bone Substitutes Plc, Company Announcement, Insider information, 5 June 2023 at 09.00 a.m. EEST

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN PART, DIRECTLY OR INDIRECTLY, IN THE USA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION OR DISTRIBUTION IS UNLAWFUL.

BBS-Bioactive Bone Substitutes Plc: BBS arranges a rights offering of approximately maximum 2.9 MEUR

Based on authorization granted by the Annual General Meeting on 30 March 2023, the Board of Directors of BBS-Bioactive Bone Substitutes Plc ("BBS" or the "Company") has decided to arrange a rights offering totaling approximately EUR 2.9 million (the "Offering"). The Offering consists of a maximum of 5,871,448 new shares (the "Offer Shares").

Summary

Approximately maximum of EUR 2.9 million before transaction costs may be raised in the Offering if fully subscribed.
The Offering is secured to approximately 27.3 per cent by subscription undertakings from the existing shareholders.
BBS will give all its shareholders registered in BBS's shareholder register maintained by Euroclear Finland Ltd ("Euroclear Finland") or Euroclear Sweden AB ("Euroclear Sweden") one (1) book-entry subscription right (the "Subscription Right") for each share held on the Offering record date. Each five (5) Subscription Rights entitles the holder to subscribe for three (3) Offer Shares.
The record date for the Offering will be 7 June 2023 with the last day of trading including the Subscription Rights on 5 June 2023 and the first day of trading excluding the Subscription Rights on 6 June 2023.
The subscription price is EUR 0.50 or SEK 5.78 per Offer Share. The subscription period for the Offer Shares (the "Subscription Period") will commence on 12 June 2023 at 10:00 Finnish time (09:00 Swedish time), and it is expected to end on 28 June 2023 at 16:00 Finnish time (15:00 Swedish time) in Finland and on 26 June 2023 in Sweden at 16:00 Finnish time (15:00 Swedish time).
Net proceeds from the Offering will be used inter alia for successful completion of the ongoing CE marking application process for BBS’ bone implant ARTEBONE Paste, for initiating the commercialisation of ARTEBONE Paste and for paying the loan repayments and interest.